Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Senneville, E.
Right arrow Articles by Mouton, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senneville, E.
Right arrow Articles by Mouton, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 927-930
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Rifampicin–ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis

Eric Sennevillea,*, Yazdan Yazdanpanaha, Marie Cazaubielb, Muriel Cordonnierb, Michel Valettea, Eric Beltrandc, Alexan Khazarjiane, Laurence Maulina, Serge Alfandaria, Michèle Caillauxd, Luc Dubreuila and Yves Moutona

a Service des Maladies Infectieuses et Tropicales , b Service d'Endocrinologie, c Service d'Orthopédie-Traumatologie and d Laboratoire de Microbiologie, Hôpital Dron, 135 rue du Pr Coty, F-59200 Tourcoing; e Service de Médecine Nucléaire Hôpital Victor Provo, F-59100 Roubaix, France

Seventeen diabetic patients with moderate to mild foot lesions associated with 20 osteomyelitic bones diagnosed by both bone scan and bone biopsy received rifampicin plus ofloxacin for a median duration of 6 months. Cure was defined as disappearance of all signs and symptoms of infection at the end of the treatment and absence of relapse during follow up. At the end of the treatment period, cure was achieved in 15 patients (88.2%) and was maintained in 13 patients (76.5%) at the end of an average post-treatment follow-up of 22 months. No serious drug-related adverse events were recorded.

* Corresponding author. Tel: +33-320-694-591; Fax: +33-320-694-589; E-mail: esenneville{at}ch-tourcoing.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
G. Euba, O. Murillo, N. Fernandez-Sabe, J. Mascaro, J. Cabo, A. Perez, F. Tubau, R. Verdaguer, F. Gudiol, and J. Ariza
Long-Term Follow-Up Trial of Oral Rifampin-Cotrimoxazole Combination versus Intravenous Cloxacillin in Treatment of Chronic Staphylococcal Osteomyelitis
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2672 - 2676.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
B. A. Lipsky, A. R. Berendt, H. G. Deery, J. M. Embil, W. S. Joseph, A. W. Karchmer, J. L. LeFrock, D. P. Lew, J. T. Mader, C. Norden, et al.
Diagnosis and Treatment of Diabetic Foot Infections
J Am Podiatr Med Assoc, March 1, 2005; 95(2): 183 - 210.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.